Keros Buyback Monday, November 16, 2026 +0.25 Positive

Keros Board approves $5M share buyback after milestone payment

Keros Therapeutics authorized a $5 million share repurchase program following a milestone payment from Takeda related to its elritercept pipeline. The biopharmaceutical company has flexibility to repurchase shares based on market conditions.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed